Sartorius Stedim Biotech S.A. (SRTOY) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 61.79 means the share price is 61.79 times one year of earnings per share; the S&P 500 usually sits near 20-25.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerSartorius Stedim Biotech S.A. (SRTOY) trades at $22.02. Sartorius Stedim Biotech S.A. is a leading international partner of the biopharmaceutical industry. The company provides a comprehensive suite of equipment and services for biopharmaceutical manufacturing processes. Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for SRTOY: SRTOY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SRTOY against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
SRTOY: the 2 scored disciplines are evenly split. Dominant signal: Ken Griffin bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Sartorius Stedim Biotech S.A. (SRTOY) Healthcare & Pipeline Overview
Sartorius Stedim Biotech S.A. provides biopharmaceutical companies with cutting-edge equipment and services for manufacturing processes, including cell culture, fermentation, filtration, and purification. The company's comprehensive portfolio and global reach position it as a key player in the rapidly growing biopharmaceutical industry, serving manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories.
What Is the Investment Thesis for SRTOY?
Sartorius Stedim Biotech S.A. presents a notable research candidate due to its strong position in the growing biopharmaceutical market. The company's comprehensive product portfolio and service offerings cater to the increasing demand for biologics and advanced therapies. With a P/E ratio of 61.79 and a profit margin of 9.0%, Sartorius Stedim Biotech demonstrates solid profitability. Key growth catalysts include the expansion of cell and gene therapy manufacturing and the increasing adoption of single-use technologies. The company's high gross margin of 45.3% reflects its pricing power and value-added solutions. However, potential risks include increasing competition and fluctuations in currency exchange rates.
Based on FMP financials and quantitative analysis
SRTOY Key Highlights
Market capitalization of $192.83 billion reflects investor confidence in the company's growth prospects.
- P/E ratio of 61.79 indicates a premium valuation, reflecting expectations of future earnings growth.
- Profit margin of 9.0% demonstrates the company's ability to generate profits from its operations.
- Gross margin of 45.3% highlights the company's strong pricing power and efficient cost management.
- Dividend yield of 0.39% provides a modest income stream for investors.
Who Are SRTOY's Competitors?
SRTOY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AZNCF AstraZeneca PLC | $189.90 | -1.35% | $294B | — |
| ESLOF EssilorLuxottica S.A. | $171.57 | -4.45% | $78.9B | — |
| FSNUY Fresenius SE & Co. KGaA | $13.00 | +0.62% | $117B | — |
| NONOF Novo Nordisk A/S | $43.19 | -2.15% | $192B | — |
| ISRG Intuitive Surgical, Inc. | $368.93 | +2.35% | $130B | 935-pillar |
| BDX Becton, Dickinson and Company | $176.42 | -1.88% | $48.6B | 705-pillar |
| ALC Alcon Inc. | $66.55 | -2.75% | $32.5B | 765-pillar |
| RMD ResMed Inc. | $218.27 | -0.60% | $31.7B | 935-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SRTOY's Key Strengths?
Leading market position in biopharmaceutical manufacturing solutions.
- Comprehensive product portfolio and service offerings.
- Strong brand reputation and customer relationships.
- Global presence and distribution network.
What Are SRTOY's Weaknesses?
High valuation compared to peers.
- Dependence on the biopharmaceutical industry.
- Exposure to currency exchange rate fluctuations.
- Potential for product recalls or quality issues.
What Could Drive SRTOY Stock Higher?
SRTOY catalyst: Increasing demand for biopharmaceutical manufacturing solutions driven by the growth of biologics and advanced therapies.
- Expansion of cell and gene therapy manufacturing capabilities to capitalize on the rapidly growing market.
- Potential acquisitions of companies in complementary areas to expand product portfolio and technological capabilities.
- Adoption of single-use technologies in biopharmaceutical manufacturing, driving demand for Sartorius Stedim Biotech's products.
- Growth in emerging markets, such as China and India, driving demand for biopharmaceutical manufacturing solutions.
What Are the Key Risks for SRTOY?
Rich valuation — a P/E of 61.79 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.
- Increasing competition from other suppliers of biopharmaceutical manufacturing solutions.
- Technological obsolescence of existing products and services.
- Changes in regulatory requirements affecting the biopharmaceutical industry.
- Economic downturns affecting the demand for biopharmaceutical products.
- Exposure to currency exchange rate fluctuations.
What Are the Growth Opportunities for SRTOY?
- Expansion in Cell and Gene Therapy: The cell and gene therapy market is experiencing rapid growth, driven by breakthroughs in research and increasing regulatory approvals. Sartorius Stedim Biotech is well-positioned to capitalize on this trend by providing specialized equipment and services for cell and gene therapy manufacturing. This market is projected to reach $55.96 billion by 2029, growing at a CAGR of 32.3% from 2021. Sartorius Stedim Biotech's expertise in cell culture, viral vector production, and purification makes it a valuable partner for companies developing these advanced therapies.
- Adoption of Single-Use Technologies: Single-use technologies are increasingly being adopted in biopharmaceutical manufacturing due to their advantages in terms of reduced cleaning and sterilization requirements, lower capital investment, and increased flexibility. Sartorius Stedim Biotech offers a comprehensive range of single-use products, including bioreactors, filters, and fluid management systems. The global single-use bioprocessing market is expected to reach $49.6 billion by 2033, growing at a CAGR of 14.2% from 2023. This trend provides a significant growth opportunity for Sartorius Stedim Biotech.
- Growth in Emerging Markets: Emerging markets, such as China and India, are experiencing rapid growth in their biopharmaceutical industries, driven by increasing healthcare spending and a growing demand for biologics. Sartorius Stedim Biotech is expanding its presence in these markets by establishing local manufacturing facilities and sales offices. This expansion allows the company to better serve its customers in these regions and capitalize on the growth opportunities. The Asia-Pacific biopharmaceutical market is projected to grow at a CAGR of 11.7% from 2024 to 2032.
- Development of Data Analytics Software: Data analytics is playing an increasingly important role in biopharmaceutical manufacturing, enabling companies to optimize their processes, improve product quality, and reduce costs. Sartorius Stedim Biotech offers data analytics software for modeling and optimizing biopharmaceutical development and production processes. This software provides valuable insights into process performance and helps companies make data-driven decisions. The global biopharmaceutical analytical testing services market is expected to reach $7.1 billion by 2028, growing at a CAGR of 8.3% from 2021.
- Strategic Acquisitions: Sartorius Stedim Biotech has a history of making strategic acquisitions to expand its product portfolio, enhance its technological capabilities, and strengthen its market position. The company is likely to continue to pursue acquisitions in areas such as cell and gene therapy, single-use technologies, and data analytics. These acquisitions can provide Sartorius Stedim Biotech with access to new markets, technologies, and customers, accelerating its growth and increasing its competitive advantage. The company's strong financial position allows it to pursue these opportunities effectively.
What Are SRTOY's Competitive Advantages?
- Strong brand reputation and established customer relationships.
- Comprehensive product portfolio and service offerings.
- Technological expertise and innovation.
- Global presence and distribution network.
- High switching costs for customers due to regulatory requirements and process validation.
What Does SRTOY Do?
Founded in 1870 and headquartered in Aubagne, France, Sartorius Stedim Biotech S.A. has evolved into a prominent provider of innovative technologies and services for the biopharmaceutical industry. Originally focused on precision weighing technology, Sartorius expanded its offerings to meet the evolving needs of biopharmaceutical manufacturers. The company offers a comprehensive range of products, including cell lines, cell culture media, bioreactors, and solutions for separation, purification, and concentration processes. These products are crucial for the development and production of biologics, vaccines, and cell and gene therapies. Sartorius Stedim Biotech also provides services such as cell cultivation, fermentation, filtration, purification, and fluid management, supporting customers throughout the entire biopharmaceutical manufacturing process. The company's solutions are used by manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. As a subsidiary of Sartorius AG, Sartorius Stedim Biotech benefits from a strong parent company with a long history of innovation and a global presence.
What Products and Services Does SRTOY Offer?
- Develops and manufactures equipment for biopharmaceutical production.
- Provides consumables such as cell culture media and filters.
- Offers bioreactors for cell cultivation and fermentation.
- Supplies solutions for separation, purification, and concentration.
- Provides systems for storage and transportation of biological products.
- Offers cell cultivation, fermentation, filtration, and purification services.
- Provides data analytics software for biopharmaceutical development and production.
- Offers single-use and reusable hollow-fiber membrane devices.
How Does SRTOY Make Money?
- Sells equipment and consumables to biopharmaceutical manufacturers.
- Provides services related to biopharmaceutical manufacturing processes.
- Generates revenue through long-term contracts and recurring sales of consumables.
- Offers customized solutions tailored to specific customer needs.
What Industry Does SRTOY Operate In?
Sartorius Stedim Biotech S.A. operates within the biopharmaceutical manufacturing industry, which is experiencing significant growth driven by the increasing demand for biologics, vaccines, and cell and gene therapies. The market is characterized by technological advancements, stringent regulatory requirements, and a growing emphasis on process efficiency and cost reduction. Sartorius Stedim Biotech competes with other suppliers of bioprocessing equipment and services, including AZNCF (Asahi Kasei Corporation), ESLOF (Eppendorf SE), ESLOY (Entegris, Inc.), FSNUY (Fujifilm Holdings Corporation), and NONOF (Novo Holdings A/S). The company's focus on innovation, quality, and customer service positions it as a leading player in this competitive landscape.
Who Are SRTOY's Key Customers?
- Biopharmaceutical manufacturers
- Pharmaceutical companies
- Food and chemical manufacturers
- Research and development laboratories
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 73 days ago
- ● No analyst coverage
- ● Reported in EUR, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 20 snapshots
| 2026-08-23 | 51 |
| 2026-08-27 | 51 |
| 2026-08-31 | 51 |
| 2026-09-04 | 51 |
| 2026-09-08 | 51 |
| 2026-09-11 | 51 |
What changed?
The score has stayed at 51.
Over the same 19 days the stock moved -2.7%.
Sartorius Stedim Biotech S.A. Financial Trajectory
Sartorius Stedim Biotech S.A. (SRTOY) reported $903.1M in revenue for Q2 FY2026, reflecting 0.6% growth compared to the prior quarter. The company recorded net income of $109.7M, with diluted EPS of $0.01. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this unknown Healthcare company. Across the four most recent quarters, SRTOY averaged $0.01 in diluted EPS.
Company Profile
Sartorius Stedim Biotech S.A. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Aubagne, FR. The company is led by CEO Rene Faber. SRTOY has traded publicly since 2022.
Key Financial Metrics
Return on equity for Sartorius Stedim Biotech S.A. stands at 7.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.7%, showing how much profit it generates from its asset base. SRTOY trades at a trailing price-to-earnings ratio of 61.79, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 1.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.16 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 1.6%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Sartorius Stedim Biotech S.A.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 32.08 places it in the safe zone, indicating low near-term bankruptcy risk.
SRTOY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Leading market position in biopharmaceutical manufacturing solutions.
- Comprehensive product portfolio and service offerings.
- Strong brand reputation and customer relationships.
- Global presence and distribution network.
Bear Case
- High valuation compared to peers.
- Dependence on the biopharmaceutical industry.
- Exposure to currency exchange rate fluctuations.
- Potential for product recalls or quality issues.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $903M | $110M | $0.01 |
| Q1 FY2026 | $898M | $104M | $0.01 |
| Q4 FY2025 | $888M | $43M | $0.01 |
| Q3 FY2025 | $817M | $74M | $0.01 |
Q2 FY2026 · filed 30 Jun 2026 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Converted to USD from EUR at today's rate
SRTOY Latest News
-
Sartorius Stedim Biotech S.A. (SRTOY) Q2 2026 Earnings Call Transcript
seekingalpha.com · Jul 24, 2026
SRTOY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SRTOY.
Price Targets
Wall Street price target analysis for SRTOY.
SRTOY MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for SRTOY; grades run from A+ (80-100) to F (below 30).
Sartorius Stedim Biotech S.A. ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. SRTOY is an ADR that allows U.S. investors to invest in Sartorius Stedim Biotech S.A. without directly dealing with foreign markets. Each SRTOY ADR represents a certain number of Sartorius Stedim Biotech S.A. shares traded on its home market.
- Home Market Ticker: Euronext Paris, France
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: SRTO
SRTOY OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Sartorius Stedim Biotech S.A. (SRTOY) has limited regulatory oversight and disclosure requirements compared to companies listed on major exchanges like the NYSE or NASDAQ. Companies in this tier may not meet minimum financial standards or reporting requirements, leading to increased risks for investors due to potential information asymmetry and lack of transparency.
- OTC Tier: OTC Other
- Limited regulatory oversight and disclosure requirements.
- Potential for information asymmetry and lack of transparency.
- Lower trading volumes and wider bid-ask spreads.
- Increased price volatility.
- Higher risk of fraud or manipulation.
- Verify the company's registration and legal status.
- Research the company's management team and their track record.
- Attempt to obtain and review any available financial statements.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal disputes involving the company.
- Subsidiary of Sartorius AG, a well-established company.
- Operates in the biopharmaceutical industry, a sector with high growth potential.
- Has a long operating history, founded in 1870.
- Presence of a known CEO, Rene Faber.
Sartorius Stedim Biotech S.A. Healthcare Stock: Key Questions Answered
Is SRTOY a good stock?
Stock Expert AI does not rate SRTOY buy, sell or hold. Sartorius Stedim Biotech S.A. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What does Sartorius Stedim Biotech S.A. do?
Sartorius Stedim Biotech S.A. is a leading provider of equipment and services for the biopharmaceutical industry. The company offers a comprehensive range of products, including cell lines, cell culture media, bioreactors, and solutions for separation, purification, and concentration processes.
What are the key factors to evaluate for SRTOY?
Evaluate SRTOY on fundamentals, analyst consensus, and risk factors. P/E: 61.79x vs the S&P 500's ~20-25x. Sartorius Stedim Biotech S.A. presents a notable research candidate due to its strong position in the growing biopharmaceutical market. Not financial advice.
How frequently does SRTOY data refresh on this page?
SRTOY's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 calculations are scheduled daily at 10:15 UTC; the score's own date shows its last successful run.
What has driven SRTOY's recent stock price performance?
Sartorius Stedim Biotech S.A. (SRTOY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Leading market position in biopharmaceutical manufacturing solutions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SRTOY overvalued or undervalued right now?
Sartorius Stedim Biotech S.A. (SRTOY) trades at 61.79x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of SRTOY?
Yes, most major brokerages offer fractional shares of Sartorius Stedim Biotech S.A. (SRTOY) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track SRTOY's earnings and financial reports?
Sartorius Stedim Biotech S.A. (SRTOY) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for SRTOY earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information on Rene Faber's background and track record is not available in the provided data.
- Analyst consensus on SRTOY stock is not available in the provided data.